 Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with relapsedrefractory B-cell NHL. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsedrefractory B-cell NHL expected in 2023. 